MarketCapExport financials
Natus Medical Incorporated (NTUS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Natus Medical Incorporated Balance Sheet 2021-2008 | NTUS
Brief overview of Natus Medical Incorporated's balance sheet strength
The review uses the five latest available annual reports between 2017 and 2021.
The asset base decreased -20.5%, from $709.9 million to $564.3 million. Resources became smaller over the five periods.
Liabilities grew more slowly than assets: -51.5% versus -20.5%. Expansion relied more on equity, improving funding quality.
Equity funds 75.3% of assets versus 59.5% initially. This creates a conservative balance sheet structure.
Net debt moved below zero to -$64.1 million, reflecting surplus cash over debt.
The cash share moved from 12.5% to 13.4%. A higher figure generally provides more room in an adverse scenario.
Retained earnings reached $84.5 million, changing -34.6% over the period. A positive accumulated result supports equity.
What the balance sheet shows
Natus Medical Incorporated's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Natus Medical Incorporated
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-64.1 M | -69.5 M | -37.8 M | 48.1 M | 65.3 M | -73.6 M | -82.5 M | -66.6 M | -18.1 M | -1.5 M | -31.9 M | -27.5 M | - | - |
Long Term Debt |
6.57 M | 5.84 M | 19.7 M | 69.5 M | 154 M | 140 M | - | - | 27.5 M | 13 M | 710 K | 737 K | - | - |
Long Term Debt Current |
4.96 M | 6.78 M | 5.87 M | 35 M | - | - | - | - | 10.5 M | 8.53 M | 188 K | 156 K | - | - |
Total Non Current Liabilities |
- | 43.5 M | 63.6 M | 106 M | 196 M | 152 M | 11.7 M | 13 M | 40 M | 24.5 M | 15.9 M | - | - | - |
Total Current Liabilities |
115 M | 146 M | 143 M | 133 M | 92.1 M | 79.9 M | 77.1 M | 69.1 M | 81.2 M | 98.6 M | 41.3 M | 44.2 M | - | - |
Total Liabilities |
140 M | 189 M | 206 M | 240 M | 288 M | 232 M | 88.8 M | 82.1 M | 121 M | 123 M | 56.5 M | 67 M | - | - |
Deferred Revenue |
25.1 M | 21.3 M | 20.2 M | 17.1 M | 15.2 M | 23.3 M | 11.3 M | 11.7 M | 12.9 M | 13.3 M | 7.6 M | 4.74 M | - | - |
Retained Earnings |
84.5 M | 71.3 M | 87.9 M | 102 M | 129 M | 149 M | 107 M | 68.9 M | 36.4 M | 13.3 M | 9.44 M | 18.9 M | 6.99 M | - |
Total Assets |
564 M | 600 M | 623 M | 638 M | 710 M | 649 M | 479 M | 435 M | 429 M | 392 M | 315 M | 331 M | - | - |
Cash and Cash Equivalents |
75.6 M | 82.1 M | 63.3 M | 56.4 M | 89 M | 214 M | 82.5 M | 66.6 M | 56.1 M | 23.1 M | 32.8 M | 28.4 M | 32.6 M | 56.9 M |
Book Value |
425 M | 411 M | 416 M | 398 M | 422 M | 417 M | 391 M | 353 M | 308 M | 269 M | 258 M | 264 M | - | - |
Total Shareholders Equity |
425 M | 411 M | 416 M | 398 M | 422 M | 417 M | 391 M | 353 M | 308 M | 270 M | 260 M | 264 M | 244 M | 227 M |
All numbers in USD currency
Quarterly Balance Sheet Natus Medical Incorporated
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 5.76 M | - | - | - | - | 5.84 M | 25.7 M | 51.8 M | 64.7 M | 19.7 M | 34.6 M | 44.6 M | 64.5 M | 69.5 M | 84.4 M | 119 M | 129 M | 154 M | 154 M | 109 M | 150 M | 140 M | 140 M | 140 M | 140 M | - | - | - | - | - | 27.5 M | 6 M | 22.5 M | 27.5 M | 37.5 M | 40.4 M | 10.9 M | 13 M | 15.2 M | 17.3 M | 675 K | 710 K | 619 K | 658 K | 710 K |
Total Liabilities |
- | - | - | 137 M | 140 M | 139 M | 138 M | 172 M | 189 M | 201 M | 225 M | 249 M | 206 M | 223 M | 226 M | 271 M | 240 M | 244 M | 256 M | 266 M | 288 M | 279 M | 236 M | 268 M | 232 M | 101 M | 89.9 M | 80.4 M | 88.8 M | 89.1 M | 80.1 M | 85.2 M | 82.1 M | 83.1 M | 89.3 M | 109 M | 121 M | 127 M | 125 M | 135 M | 123 M | 129 M | 89 M | 56.3 M | 56.5 M | 56.3 M | 58.5 M | 56.6 M |
Deferred Revenue |
- | - | - | 26.8 M | 25.1 M | 25.7 M | 24.5 M | 23.7 M | 21.3 M | 20 M | 21.2 M | 22.8 M | 20.2 M | 19.2 M | 19.9 M | 19 M | 17.1 M | 16.8 M | 16.9 M | 16.6 M | 15.2 M | 14.7 M | 14.8 M | 14.8 M | 23.3 M | 33.3 M | 11.3 M | 11.5 M | 11.3 M | 10.2 M | 11.1 M | 12 M | 11.7 M | 11.7 M | 11.4 M | 11.8 M | 12.9 M | 12.4 M | 12 M | 14.1 M | 13.3 M | 11.8 M | 7.72 M | 8.09 M | 7.6 M | 7.07 M | 5.1 M | 7.6 M |
Retained Earnings |
- | - | - | 86.4 M | 84.5 M | 82.7 M | 77.2 M | 73.7 M | 71.3 M | 66.1 M | 75.4 M | 84.3 M | 87.9 M | 86.2 M | 77.8 M | 73.6 M | 102 M | 114 M | 119 M | 122 M | 129 M | 136 M | 145 M | 150 M | 149 M | 139 M | 126 M | 115 M | 107 M | 98.3 M | 87.3 M | 77.5 M | 68.9 M | 56.3 M | 48.5 M | 40.8 M | 36.4 M | 25.4 M | 19.1 M | 15.1 M | 13.3 M | 6.03 M | 7.97 M | 7.53 M | 9.44 M | 23.7 M | 23.5 M | 7.17 M |
Total Assets |
- | - | - | 568 M | 564 M | 561 M | 556 M | 581 M | 600 M | 597 M | 621 M | 647 M | 623 M | 629 M | 628 M | 639 M | 638 M | 654 M | 664 M | 683 M | 710 M | 704 M | 663 M | 689 M | 649 M | 511 M | 486 M | 473 M | 479 M | 470 M | 454 M | 444 M | 435 M | 415 M | 420 M | 429 M | 429 M | 416 M | 405 M | 408 M | 392 M | 389 M | 348 M | 316 M | 315 M | 331 M | 334 M | 314 M |
Cash and Cash Equivalents |
- | - | - | 84.3 M | 75.6 M | 68.8 M | 62.5 M | 80.5 M | 82.1 M | 74.5 M | 84.9 M | 107 M | 63.3 M | 63.1 M | 52 M | 53.4 M | 56.4 M | 54.4 M | 54.9 M | 64.5 M | 89 M | 132 M | 80.3 M | 104 M | 214 M | 81.1 M | 96.3 M | 81.3 M | 82.5 M | 82.2 M | 73.2 M | 67 M | 66.6 M | 57.8 M | 56 M | 59.6 M | 56.1 M | 44.2 M | 28.9 M | 24.4 M | 23.1 M | 19.5 M | 17 M | 37.4 M | 32.8 M | 30.8 M | 37.7 M | 32.8 M |
Book Value |
- | - | - | 431 M | 425 M | 423 M | 418 M | 409 M | 411 M | 395 M | 395 M | 398 M | 416 M | 406 M | 402 M | 368 M | 398 M | 410 M | 408 M | 417 M | 422 M | 425 M | 426 M | 420 M | 417 M | 409 M | 396 M | 392 M | 391 M | 381 M | 374 M | 359 M | 353 M | 332 M | 330 M | 320 M | 308 M | 289 M | 279 M | 273 M | 269 M | 260 M | 259 M | 260 M | 258 M | 275 M | 275 M | 258 M |
Total Shareholders Equity |
- | - | - | 431 M | 425 M | 423 M | 418 M | 409 M | 411 M | 395 M | 395 M | 398 M | 416 M | 406 M | 402 M | 368 M | 398 M | 410 M | 408 M | 417 M | 422 M | 425 M | 426 M | 420 M | 417 M | 409 M | 396 M | 392 M | 391 M | 381 M | 374 M | 359 M | 353 M | 332 M | 330 M | 320 M | 308 M | 289 M | 279 M | 273 M | 270 M | 260 M | 259 M | 260 M | 260 M | 275 M | 275 M | 258 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Natus Medical Incorporated, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical devices
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Conformis
CFMS
|
- | - | $ 16.4 M |  USA |
 |
Bruker Corporation
BRKR
|
$ 64.0 | 7.26 % | $ 9.72 B | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 0.06 % | $ 66.1 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.7 | 0.06 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.61 | 13.03 % | $ 414 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.18 | 3.31 % | $ 1.4 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.3 | 1.63 % | $ 268 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
$ 16.08 | 0.75 % | $ 576 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
$ 27.86 | 1.05 % | $ 230 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 65.58 | 3.69 % | $ 1.94 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 85.73 | 0.32 % | $ 50.1 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
AdaptHealth Corp.
AHCO
|
$ 5.57 | 0.43 % | $ 753 M | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.9 | 0.69 % | $ 63.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.88 | 2.25 % | $ 1.22 B | USA |
 |
Inogen
INGN
|
$ 5.23 | 2.75 % | $ 139 M | USA |
 |
InMode Ltd.
INMD
|
$ 14.19 | 0.21 % | $ 917 M | Israel |
 |
Inspire Medical Systems
INSP
|
$ 68.81 | 0.59 % | $ 2.02 B | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 2.51 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 85.2 | 0.08 % | $ 1.08 B | USA |
 |
AxoGen
AXGN
|
$ 43.32 | 0.48 % | $ 1.99 B | USA |
 |
Align Technology
ALGN
|
$ 145.63 | 4.36 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
$ 7.08 | 0.28 % | $ 84.7 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Medtronic PLC
MDT
|
$ 88.51 | 0.32 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.71 | 0.1 % | $ 696 M | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
$ 1.67 | 1.83 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.66 | 0.45 % | $ 42.8 M | Israel |
 |
InspireMD
NSPR
|
$ 0.7 | 0.37 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.16 | 0.11 % | $ 363 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.13 | 1.29 % | $ 47.6 K | USA |
 |
Insulet Corporation
PODD
|
$ 135.78 | 0.01 % | $ 9.55 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.6 | 1.66 % | $ 169 M | Canada |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.18 | 0.63 % | $ 136 M | USA |
 |
AVITA Medical
RCEL
|
$ 11.58 | 5.75 % | $ 323 M |  Australia |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.83 | 1.37 % | $ 116 M | USA |
 |
Sintx Technologies
SINT
|
$ 1.87 | 5.06 % | $ 5.19 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.22 | 0.4 % | $ 27 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.68 | 0.02 % | $ 23.1 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |